MRC1 and neoplasm: Notably, neither acetazolamide, a CA12 inhibitor (CAi), nor anti–PD-1 treatment could affect the expression of CD204 and CD206 on tumor-infiltrating macrophages compared with control (Supplemental Figure 8C).